The legal framework governing retatrutide in the United States — and the enforcement actions taken against those who violate it. Understanding the law is essential context for anyone researching this drug.
The primary federal law governing drugs in the United States. Under the FD&C Act, a drug cannot be legally marketed in the U.S. without FDA approval (an approved NDA or ANDA). Retatrutide has no approved NDA. Selling or distributing retatrutide for human use outside of an authorized clinical trial violates the FD&C Act.
Relevance to retatrutide: Directly applies to retatrutide. Any vendor selling retatrutide for human use is violating this law.
The IND exemption allows a drug to be administered to humans in the context of an authorized clinical trial. Eli Lilly holds an active IND for retatrutide. This exemption applies only to trial participants at authorized sites — it does not authorize general use.
Relevance to retatrutide: Retatrutide can only be legally used in humans within the TRIUMPH trials or other authorized Lilly-sponsored studies.
Section 503A permits traditional compounding pharmacies to prepare customized medications for individual patients based on a valid prescription. 503A pharmacies cannot compound copies of commercially available drugs or drugs on the FDA's "difficult to compound" list. Retatrutide is not eligible for 503A compounding because it has no approved NDA.
Relevance to retatrutide: Compounding pharmacies cannot legally prepare retatrutide for human use.
Section 503B governs larger-scale outsourcing facilities that can produce drugs without patient-specific prescriptions. 503B facilities are FDA-registered and inspected. Like 503A, 503B cannot be used for retatrutide because it is an unapproved investigational drug.
Relevance to retatrutide: Outsourcing facilities cannot legally produce retatrutide for human use.
RUO is a designation for laboratory reagents and chemical compounds sold for in-vitro or animal research only. RUO products are not manufactured to pharmaceutical standards and are not intended for human use. Selling RUO compounds with the intent that they will be used in humans violates the FD&C Act regardless of the RUO label.
Relevance to retatrutide: Vendors cannot use the RUO label to circumvent FDA drug approval requirements when the intended use is human administration.
FDA's personal importation policy allows individuals to import small quantities of unapproved drugs for personal use under limited circumstances — generally for serious conditions with no domestic alternative. This policy is discretionary and does not apply to drugs being actively marketed in the U.S. by unapproved vendors. It does not create a legal right to import retatrutide.
Relevance to retatrutide: Personal importation of retatrutide is legally risky and not protected by FDA policy.
FDA and DOJ enforcement actions relevant to unapproved peptide compounds and GLP-1 analogs. Sourced from public agency records.
FDA issued warning letters to multiple vendors selling unapproved peptide compounds — including retatrutide analogs — labeled as "research use only." The letters cited violations of the FD&C Act for marketing unapproved drugs for human use and directed vendors to cease distribution.
SourceFDA updated its compounding guidance to clarify that retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under 503A or 503B frameworks. The guidance addressed increasing inquiries from compounding pharmacies following the GLP-1 compounding controversy.
SourceThe Department of Justice, in coordination with FDA, pursued criminal charges against an online distributor selling unapproved injectable peptides including GLP-1 analogs. The case highlighted the legal risks for both vendors and, in some jurisdictions, purchasers of unapproved compounds.
SourceThe Federal Trade Commission took action against online vendors making unsubstantiated efficacy claims about unapproved weight loss compounds, including peptides marketed as equivalent to FDA-approved GLP-1 drugs. Actions included cease-and-desist orders and civil penalties.
SourceFDA issued an import alert covering unapproved peptide compounds manufactured abroad and shipped to U.S. consumers. The alert authorized detention without physical examination of shipments from flagged manufacturers.
Source